Skip to content

Pharmacogenetics of Antidepressant-Induced Disinhibition

Anxiety Disorders | Major Depressive Disorder | Obsessive-Compulsive Disorder | Antidepressant Drug Adverse Reaction

The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and/or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    6 to 17

Participation Criteria

Inclusion Criteria:

1. Aged 6 - 24 years
2. Medical records available
3. Diagnosis of MDD, anxiety disorder, or OCD
4. Current or past history of SSRI therapy

Exclusion Criteria:

1. Inability of parent/legal guardian to give informed consent
2. Inability of the child to give informed assent
3. Unwillingness of child to provide saliva sample for genetic analysis
4. Current, past or suspected diagnosis of attention deficit hyperactivity disorder, oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, or pervasive developmental disorder.

Study Location

Child and Adolescent Addiction, Mental Health & Psychiatry
Child and Adolescent Addiction, Mental Health & Psychiatry
Calgary, Alberta
Canada

Contact Study Team

Primary Contact

Madison Heintz, MSW

Study Sponsored By
University of Calgary
Participants Required
More Information
Study ID: NCT03953014